Cover Image
市場調查報告書

EpiCast Report:非何杰金氏淋巴瘤(NHL)的流行病學預測

EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 301409
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:非何杰金氏淋巴瘤(NHL)的流行病學預測 EpiCast Report: Non-Hodgkin's Lymphoma - Epidemiology Forecast to 2024
出版日期: 2016年01月01日 內容資訊: 英文 67 Pages
簡介

所謂非何杰金氏淋巴瘤(NHL),是發達於淋巴系統的一種癌症,會造成惡性白血球無限制地增生,對人體免疫系統造成不良影響,使人體無法對抗傳染病及其他疾病。NHL可分為B細胞、T細胞、自然殺手三種,先進國家B細胞最為常見。儘管有許多研究,NHL目前仍然幾乎無法治癒,且其原因也仍不可解。全球主要六個國家的B細胞NHL患者數預測將從2013年的89,455人,擴大到2023年的111,366人(這期間的年平均成長率(CAGR)為2.45%)。美國擁有最多患者人數(2023年預測為56,033人)其次為德國(2023年預測為17,176人)、英國(2023年預測為12,548人)。

本報告提供全球主要6個國家(美國·法國·德國·義大利·西班牙·英國)的非何杰金氏淋巴瘤(NHL)發病情形和今後預測相關分析,提供疾病的特徵(風險要素和主要的合併症等等)及全球各國的趨勢,目前患病者的發病情形,今後10年的發病·病患數的預測值等調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和合併症
  • 全世界的趨勢
    • 美國
    • 歐洲5個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
    • 年齡已調整的罹患率
  • B細胞NHL的流行病學的預測(今後11年份)
    • 濾泡性淋巴瘤
    • 周邊區域淋巴瘤
    • 瀰漫性大型B細胞淋巴癌(DLBCL)
    • 被套細胞淋巴瘤
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER113-15

Non-Hodgkin's Lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body's immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body's inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma. NHL is more common in men than in women, in white men and women compared with black men and women, and the incidence exponentially increases with age.

GlobalData epidemiologists forecast an increase in the incident cases of the four B-cell NHL in the 7MM, from 104,854 incident cases in 2014 to 129,179 incident cases in 2024, with an annual growth rate (AGR) of 2.32%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 57,724 incident cases in 2024. Additionally, each of the 7MM will see an increase in incident cases over the 10-year forecast period.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 7MM. A major strength of GlobalData's epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 7MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the seven markets. Furthermore, GlobalData epidemiologists constructed and analyzed each B-cell NHL subtype individually, which facilitated an in-depth understanding of B-cell NHL in the 7MM.

Scope

  • The Non-Hodgkin's Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for NHL in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the incident cases of NHL segmented by sex, age (in five-year increments beginning at 30 years and ending at =85 years), and subtypes in these markets.
  • The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The NHL EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global NHL market.
  • Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for B-Cell NHL (2014-2024)
    • 3.5.1. Follicular Lymphoma
    • 3.5.2. Marginal Zone Lymphoma
    • 3.5.3. DLBCL
    • 3.5.4. Mantle Cell Lymphoma
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for NHL
  • Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010
  • Table 3: 7MM, Sources of B-Cell NHL Incidence Data
  • Table 4: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 5: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014
  • Table 6: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 7: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 8: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014
  • Table 9: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 10: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 11: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014
  • Table 12: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2014
  • Table 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014
  • Table 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2014

List of Figures

  • Figure 1: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 4: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 5: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 7: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 8: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 9: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 10: 7MM, Age-Specific Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 11: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2014
  • Figure 12: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 13: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 14: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014
  • Figure 15: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 16: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
Back to Top